News
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...
Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...
Novo Nordisk is expanding access to its GLP-1 drug Wegovy via telehealth, partnering with Hims and Hers, Ro, and LifeMD.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback